Johnson Matthey (OTCMKTS:JMPLY – Get Free Report) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.
Other research analysts also recently issued reports about the stock. Citigroup reissued a “neutral” rating on shares of Johnson Matthey in a report on Tuesday, October 21st. Jefferies Financial Group raised Johnson Matthey to a “strong-buy” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Johnson Matthey currently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Report on JMPLY
Johnson Matthey Stock Up 0.6%
About Johnson Matthey
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
See Also
- Five stocks we like better than Johnson Matthey
- What Are Dividend Achievers? An Introduction
- MarketBeat Week in Review – 11/03 – 11/07
- What is the Australian Securities Exchange (ASX)
- OpenAI’s Restructuring Sets up What Could Be the Biggest IPO Ever
- The 3 Best Blue-Chip Stocks to Buy Now
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
